Fool - Investing News·1d ago
3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any MarketThey are so much more than just dividend stocks.
Medtronic's revenue growth has accelerated to 13.7% year-over-year in Q1 FY2027, suggesting its portfolio optimization strategy is gaining traction.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 13.7% year-over-year in Q1 FY2027, but operating margin remains constrained at 18.1% due to elevated SG&A spending of $3.2B (33% of revenue), suggesting growth investments are currently offsetting scale benefits.
Medtronic is a global leader in medical technology, services, and solutions, collaborating to address healthcare challenges.
Medtronic's strong competitive positioning and wide moat support its long-term business resilience and growth.
The company's innovation pipeline, including products like the Stealth AXiS surgical system, drives future growth opportunities.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Sep 1, 2026 | $1.45+4.3% vs $1.39 | $9.8B+2.2% vs $9.5B |
Q3 2026 Jun 3, 2026 | $1.55+0.6% vs $1.54 | $9.8B+1.9% vs $9.6B |
Q1 2026 Feb 17, 2026 | $1.36+1.5% vs $1.34 | $9.0B+1.2% vs $8.9B |
Q4 2025 Nov 18, 2025 | $1.36+3.8% vs $1.31 | $9.0B+1.1% vs $8.9B |
They are so much more than just dividend stocks.
They have both outperformed the broader equity market over the long run.
GALWAY, Ireland, Nov. 4, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, November 24, 2026, for its second quarter of fiscal year 2027, which ended on Friday, October 30, 2026. A news release containing summary financial information will be issued at 5:45 a.m.
Investment newsletters' favorite Dividend Aristocrat stocks
Benchmark MDT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Medtronic plc (MDT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $101.80 | $130.7B | 27.29 | 8.43% | 13.2% | 9.76% | 2.78% | |
| $109.93 | $191.48B | 29.55 | 5.67% | 9.75% | 9% | 2.14% | |
| $42.75 | $63.54B | 22.04 | 19.87% | 16.56% | 13.74% | — | |
| $102.14 | $58.81B | 55.81 | 11.55% | 15.43% | 9.66% | — | |
| $325.78 | $124.89B | 38.78 | 11.16% | 13.78% | 15.61% | 1.03% | |
| $105.59 | $20.43B | 29.74 | 7.2% | 9.48% | 6.36% | 0.91% |
Medtronic plc (MDT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Medtronic plc (MDT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Sep 1, 2026·SEC
Jun 3, 2026·SEC
May 18, 2026·SEC
Get notified when MDT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Medtronic plc (MDT) stock FAQ — growth, dividends, profitability & financials explained
Medtronic plc (MDT) reported $37.54B in revenue over the trailing twelve months. Revenue was $36.36B in fiscal year 2026. That is 1391% more than the $2.44B of fiscal year 1997.
Medtronic plc (MDT) grew revenue by 8.4% in fiscal year 2026, compared with the prior fiscal year.
Yes. Medtronic plc (MDT) earned $5.23B in net income over the trailing twelve months (a 13.9% net margin).
Yes. Medtronic plc (MDT) pays a dividend that yields 2.78% at the current price, a moderate yield.
Medtronic plc (MDT) had a return on equity (ROE) of 9.8% in fiscal year 2026. That is below the market's typical 10-15%.
Medtronic plc (MDT) generated $6.13B in free cash flow over the trailing twelve months.
